On the updated ECCO consensus guidelines for medical management of Crohn's disease

摘要

During the 2009 annual meeting of the European Crohn's and Colitis Organisation (ECCO), the updated consensus guidelines for medical management of Crohn's disease (CD) were presented. ECCO deserves recognition for using a rigorous, evidence-based approach in developing these guidelines. However, whilst we acknowledge our own interests as marketing authorisation holder and distributor of Remicade, we would like to respectfully point out our objections to an assumption of a class effect between anti-TNF agents, as the updated guidelines and in particular section 51 suggest.